MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) this week announced significant progress in expanding access to its NeuroStar TMS Therapy for patients with major depressive disorder (MDD).
BlueCross BlueShield of North Carolina has now extended coverage to adolescents aged 15 and older, a decision influenced by recent FDA clearance making NeuroStar the first TMS treatment approved for this age group. This policy change impacts over 2.2 million individuals covered by BCBS of North Carolina.
Additionally, Louisiana Medicaid has introduced its first TMS coverage for adults 18 and older, affecting over 1.6 million lives.
These developments represent a crucial step in addressing the increasing demand for effective mental health treatments amidst a shortage of providers, potentially transforming the landscape of depression care.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.